Burbank-based genetic testing firm Endocanna Well being Inc. has obtained a United States patent for its DNA check that analyzes a person’s cannabinoid neuron system to find out whether or not any hashish merchandise could trigger damaging impacts.
Based on Endocanna Well being, the patent award, which it introduced this month, is seemingly the primary patent for DNA testing associated to hashish merchandise.
The check is designed to assist customers keep away from adversarial well being impacts from hashish merchandise. Since hashish merchandise have gained authorized standing in a number of states over the previous 20 years – first for medical makes use of after which for broader and leisure makes use of – the variety of emergency room visits has skyrocketed from folks struggling extreme reactions to hashish.
For instance, in keeping with Endocanna Well being, the variety of emergency room visits by hashish customers over 65 years of age in California jumped practically twentyfold between 2005 and 2019.
This pattern has gained nationwide consideration. ABC Information’ “Nightline” earlier this month featured a section on cannabinoid hyperemesis syndrome, or CHS, a uncommon situation introduced on by excessive hashish consumption charges that ends in extreme vomiting episodes that in a couple of cases have confirmed deadly.
The information section identified that whereas the leap within the variety of emergency room visits coincided with the unfold of marijuana legalization, the leap might also be as a result of growing efficiency ranges of the marijuana merchandise consumed.
Endocanna Well being’s DNA check is designed to flag people who could be at greater threat of CHS or different adversarial reactions to hashish merchandise. Endocanna then applies a synthetic intelligence platform to advocate exact cannabinoid ratios and terpene mixtures (which yield particular moods, similar to rest or an uplifting impact) in addition to merchandise that match these profiles.
Endocanna’s genetic check platform is geared toward each hashish customers and their prescribing physicians.
“We’re proud to offer a personalised platform that successfully addresses severe well being issues whereas eradicating the related threat of adversarial reactions,” mentioned Len Might, Endocanna’s chief government.
With this evaluation in hand, Endocanna can provide the beneficial hashish product formulations and dosage allotments to every of its prospects.
“We all know that everybody responds to hashish merchandise in another way,” Might continued. “That’s why customized cannabinoid therapeutics are important to making sure higher well being outcomes. We’re thrilled to obtain the mental property safety for our complete DNA check that’s pioneering endocannabinoid compatibility.”
Might, who has researched cannabinoids and their affect on human physiology for greater than 20 years, launched Endocanna Well being in 2017. Based on an interview in Authority Journal posted on Endocanna’s web site, Might mentioned he determined to start out the corporate after observing that teams of individuals utilizing hashish to deal with the identical medical situation would have completely different reactions to the identical hashish product.
Endocanna Well being mentioned within the patent announcement that it has two different patents pending for its proprietary cannabinoid formulations and its synthetic intelligence platform.